Andrey V. Vazhenin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrey V. Vazhenin has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Alla S. Domozhirova
Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Department of Health of the City of Moscow; South Ural State Medical University
7 shared publications E A Nadvikova
6 shared publicationsA V Privalov
5 shared publications- Konstantin I. Kulaev
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
5 shared publications O S Tereshin
4 shared publicationsA A Fokin
3 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 132-138
Application of artificial intelligence in assessing the size of colon tumors during endoscopic examination
Introduction. The risk of malignancy of precancerous colonic lesions directly depends on the size of the neoplasms detected during colonoscopy. According to various authors, neoplasms up to 2.0 cm in diameter have a 12.5% risk of harboring malignant cells. If the neoplasm is larger than 2.0 cm, the risk of malignancy increases significantly and, according to various authors, ranges from 31 to 57%. The endoscopist’s subjective assessment of neoplasm size often does not correspond to the actual size, leading to inappropriate treatment decisions. Aim. To develop and evaluate the effectiveness of a hardware-based subsystem for measuring the size of colonic neoplasms (AI-assisted neoplasm size estimation, AIANSE) during colonoscopy with AI-assisted colonoscopy detection (AIAC). Materials and methods. From 2022 to 2024, the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, in collaboration with the Russian company EVA Lab, developed and implemented a clinical decision support system based on artificial intelligence algorithms. The study included 1,763 patients, from whom approximately 27,000 frames were labeled. Results. Computer processing of endoscopic images demonstrated its effectiveness in both tumor detection and tumor size estimation. This is confirmed by comparing colonoscopy image analysis data with the actual dimensions of the neoplasms determined after surgical treatment. The system possesses self-learning capabilities, as evidenced by the increase in specificity (from 63% to 70%), sensitivity (from 64% to 70%), and accuracy (from 66% to 71%) between 2022 and 2024. Conclusions. AIANSE, a computer-based tumor analysis and size measurement system, was developed for the first time. This system demonstrated its effectiveness in tumor size estimation, with an accuracy of 71%. This development demonstrated its greatest effectiveness in measuring tumor sizes of 5 mm in diameter, with an accuracy of 76%.
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 132-138
Open AccessApplication of artificial intelligence in assessing the size of colon tumors during endoscopic examination
Introduction. The risk of malignancy of precancerous colonic lesions directly depends on the size of the neoplasms detected during colonoscopy. According to various authors, neoplasms up to 2.0 cm in diameter have a 12.5% risk of harboring malignant cells. If the neoplasm is larger than 2.0 cm, the risk of malignancy increases significantly and, according to various authors, ranges from 31 to 57%. The endoscopist’s subjective assessment of neoplasm size often does not correspond to the actual size, leading to inappropriate treatment decisions. Aim. To develop and evaluate the effectiveness of a hardware-based subsystem for measuring the size of colonic neoplasms (AI-assisted neoplasm size estimation, AIANSE) during colonoscopy with AI-assisted colonoscopy detection (AIAC). Materials and methods. From 2022 to 2024, the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, in collaboration with the Russian company EVA Lab, developed and implemented a clinical decision support system based on artificial intelligence algorithms. The study included 1,763 patients, from whom approximately 27,000 frames were labeled. Results. Computer processing of endoscopic images demonstrated its effectiveness in both tumor detection and tumor size estimation. This is confirmed by comparing colonoscopy image analysis data with the actual dimensions of the neoplasms determined after surgical treatment. The system possesses self-learning capabilities, as evidenced by the increase in specificity (from 63% to 70%), sensitivity (from 64% to 70%), and accuracy (from 66% to 71%) between 2022 and 2024. Conclusions. AIANSE, a computer-based tumor analysis and size measurement system, was developed for the first time. This system demonstrated its effectiveness in tumor size estimation, with an accuracy of 71%. This development demonstrated its greatest effectiveness in measuring tumor sizes of 5 mm in diameter, with an accuracy of 76%.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report
Background . Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases. Objective : to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy. Case presentation . A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle. Conclusion . Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report
Background . Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases. Objective : to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy. Case presentation . A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle. Conclusion . Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).
- Open Access
- 9 April 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (1) , 107-110
Polyostotic fibrous dysplasia: a clinical case
Fibrous dysplasia is a benign pathological process with various manifestations. Sometimes the volume of lesions leads to «malignant» course of disease. This article presents a clinical case of a patient with a rare disabling isolated polyostotic form of fibrous dysplasia. This patient was admitted to a medical center due to the appearance of acute pain in the right lower limb and a change in the axis of the limbs. We present the case of a patient with rare disabling isolated polyostotic form of fibrous dysplasia.
- 9 April 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (1) , 107-110
Open AccessPolyostotic fibrous dysplasia: a clinical case
Fibrous dysplasia is a benign pathological process with various manifestations. Sometimes the volume of lesions leads to «malignant» course of disease. This article presents a clinical case of a patient with a rare disabling isolated polyostotic form of fibrous dysplasia. This patient was admitted to a medical center due to the appearance of acute pain in the right lower limb and a change in the axis of the limbs. We present the case of a patient with rare disabling isolated polyostotic form of fibrous dysplasia.
- Open Access
- 13 February 2024
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 12 (4) , 27-46
Psychological Predictors of Untimely Visit of Prostate Cancer Patients for Oncological Treatment
Among oncological diseases, prostate cancer ranks third after lung and stomach cancer. A timely (early) application of patients for medical help, early diagnosis and early treatment are the factors of a favourable course and survival rate. The purpose of the study is to identify a set of psychological predictors associated with untimely primary care-seeking in men with prostate cancer. 81 men diagnosed with prostate cancer took part in the study, aged from 53 to 85 years old (mean age — 64.4, standard deviation — 8.8), 42 men at early stages of the disease (I, II), 39 men at late stages (III, IV), who first sought professional medical help in the Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine, Chelyabinsk, Russia. Seeking medical help at the early stages of the disease (I, II stages) is timely, or an early application, while treatment at later stages (III, IV) is late treatment. The study used survey methods, in particular, psychodiagnostic techniques: the World Assumptions Scale (R. Janoff-Bulman; adapted by M.A. Padun, A.V. Kotelnikova), the Level of Subjective Control method (E.F. Bazhin, E.A. Golynkina, L.M. Etkind), the Life Orientation Test (M.F. Scheier, C.S. Carpenter, adapted by D.A. Tsiring, K.Y. Evnina), the S. Maddi test of resilience, adapted by D.A. Leontiev, E.I. Rasskazova, the SF-36 “Quality of Life Assessment” questionnaire (the translation into Russian and the approbation of the methodology was carried out by the Institute of Clinical and Pharmacological Research, St. Petersburg). The study found that men who do not seek medical help in a timely manner experience intense pain that interferes with their daily activity, they are also internalized in the field of industrial relations, showing more personal responsibility for successes and failures in the professional sphere. Also, men with prostate cancer who seek help in the late stages of the disease are close to a pessimistic expectation of the future.
- 13 February 2024
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 12 (4) , 27-46
Open AccessPsychological Predictors of Untimely Visit of Prostate Cancer Patients for Oncological Treatment
Among oncological diseases, prostate cancer ranks third after lung and stomach cancer. A timely (early) application of patients for medical help, early diagnosis and early treatment are the factors of a favourable course and survival rate. The purpose of the study is to identify a set of psychological predictors associated with untimely primary care-seeking in men with prostate cancer. 81 men diagnosed with prostate cancer took part in the study, aged from 53 to 85 years old (mean age — 64.4, standard deviation — 8.8), 42 men at early stages of the disease (I, II), 39 men at late stages (III, IV), who first sought professional medical help in the Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine, Chelyabinsk, Russia. Seeking medical help at the early stages of the disease (I, II stages) is timely, or an early application, while treatment at later stages (III, IV) is late treatment. The study used survey methods, in particular, psychodiagnostic techniques: the World Assumptions Scale (R. Janoff-Bulman; adapted by M.A. Padun, A.V. Kotelnikova), the Level of Subjective Control method (E.F. Bazhin, E.A. Golynkina, L.M. Etkind), the Life Orientation Test (M.F. Scheier, C.S. Carpenter, adapted by D.A. Tsiring, K.Y. Evnina), the S. Maddi test of resilience, adapted by D.A. Leontiev, E.I. Rasskazova, the SF-36 “Quality of Life Assessment” questionnaire (the translation into Russian and the approbation of the methodology was carried out by the Institute of Clinical and Pharmacological Research, St. Petersburg). The study found that men who do not seek medical help in a timely manner experience intense pain that interferes with their daily activity, they are also internalized in the field of industrial relations, showing more personal responsibility for successes and failures in the professional sphere. Also, men with prostate cancer who seek help in the late stages of the disease are close to a pessimistic expectation of the future.
- Open Access
- 30 April 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (2) , 292-299
Artificial Intelligence in Colon Neoplasm Diagnosis: Development, Implementation of Technology, and Initial Results
Введение. Проблема диагностики и лечения колоректального рака является крайне актуальной проблемой. По данным Всемирной организации здравоохранения и Международного агентства по изучению рака за 2020 г., в мире ежегодно регистрируется около 1,93 млн. случаев колоректального рака. Несмотря на постоянное совершенствование эндоскопического оборудования, число случаев пропущенного рака толстой кишки после выполнения диагностической колоноскопии колеблется от 2,1 % до 5,9 %. В диагностике предраковой патологии доля таких исследований достигает 32,8 %. Причин пропуска патологии множество, одна из которых «человеческий фактор»: частота выявленной патологии зависит от квалификации и опыта врача-эндоскописта. Цель исследования. Оценить эффективность диагностической колоноскопии с применением системы искусственного интеллекта в детекции новообразований толстого кишечника. Материалы и методы. С 2021 по 2022 гг. в ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины» совместно с российской компанией EVA Lab (ООО «ЭВА Лаб») была разработана, апробирована и внедрена система поддержки принятия врачебных решений (СППВР) на основе алгоритмов искусственного интеллекта. Исследование включает в себя анализ материалов в отношении 944 пациентов с различной патологией толстого кишечника — 338 мужчин (41,1 %) и 556 женщин (58,9 %). Средний возраст мужчин составил 64 ± 12,9 лет, женщин 63 ± 10,2 лет. Все пациенты были разделены на две группы. Первая группа (контрольная) — ретроспективная, формировалась до внедрения в 2020 г. систем на основе искусственного интеллекта, в нее вошли 634 пациента. Вторая группа (группа исследования) — это проспективная когорта, которая начала формироваться с 2020 г. (с момента внедрения системы искусственного интеллекта) включила 310 пациентов. В обеих группах диагностические колоноскопии выполнялись одними и теми же врачами-эндоскопистами со стажем не менее 10 лет. Результаты. В контрольной группе пациентов было обнаружено 358 (56,4 %) новообразований толстого кишечника, а в группе исследования — 204 (65,8 %). Наибольшая эффективность системы искусственного интеллекта достигалась при детекции новообразований до 1,0 см в диаметре. Если сравнивать частоту выявления новообразований в группе исследования и контрольной группе в категориях пациентов с размером новообразования до 0,5 см и с размерами от 0,5 до 1,0 см, то разница составит 15,7 %, т. е. в группе исследования новообразования регистрировались значимо чаще, чем в контрольной группе (р˂0,001). При размерах новообразования более 1,0 см в диаметре, существенных различий между группами контроля и исследования не обнаружено. Биопсия выполнялась на 13 % чаще в группе исследования по сравнению с контрольной группой. Заключение. Система искусственного интеллекта наглядно продемонстрировала свою эффективность в детекции новообразований любых размеров; чувствительность составила 80,7 %. Вероятность обнаружения новообразований менее 1,0 см в диаметре при использовании была выше на 13,7 %, вероятность обнаружения тубулярных аденом всех размеров выше на 9,7 %.
- 30 April 2023
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 69 (2) , 292-299
Open AccessArtificial Intelligence in Colon Neoplasm Diagnosis: Development, Implementation of Technology, and Initial Results
Введение. Проблема диагностики и лечения колоректального рака является крайне актуальной проблемой. По данным Всемирной организации здравоохранения и Международного агентства по изучению рака за 2020 г., в мире ежегодно регистрируется около 1,93 млн. случаев колоректального рака. Несмотря на постоянное совершенствование эндоскопического оборудования, число случаев пропущенного рака толстой кишки после выполнения диагностической колоноскопии колеблется от 2,1 % до 5,9 %. В диагностике предраковой патологии доля таких исследований достигает 32,8 %. Причин пропуска патологии множество, одна из которых «человеческий фактор»: частота выявленной патологии зависит от квалификации и опыта врача-эндоскописта. Цель исследования. Оценить эффективность диагностической колоноскопии с применением системы искусственного интеллекта в детекции новообразований толстого кишечника. Материалы и методы. С 2021 по 2022 гг. в ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины» совместно с российской компанией EVA Lab (ООО «ЭВА Лаб») была разработана, апробирована и внедрена система поддержки принятия врачебных решений (СППВР) на основе алгоритмов искусственного интеллекта. Исследование включает в себя анализ материалов в отношении 944 пациентов с различной патологией толстого кишечника — 338 мужчин (41,1 %) и 556 женщин (58,9 %). Средний возраст мужчин составил 64 ± 12,9 лет, женщин 63 ± 10,2 лет. Все пациенты были разделены на две группы. Первая группа (контрольная) — ретроспективная, формировалась до внедрения в 2020 г. систем на основе искусственного интеллекта, в нее вошли 634 пациента. Вторая группа (группа исследования) — это проспективная когорта, которая начала формироваться с 2020 г. (с момента внедрения системы искусственного интеллекта) включила 310 пациентов. В обеих группах диагностические колоноскопии выполнялись одними и теми же врачами-эндоскопистами со стажем не менее 10 лет. Результаты. В контрольной группе пациентов было обнаружено 358 (56,4 %) новообразований толстого кишечника, а в группе исследования — 204 (65,8 %). Наибольшая эффективность системы искусственного интеллекта достигалась при детекции новообразований до 1,0 см в диаметре. Если сравнивать частоту выявления новообразований в группе исследования и контрольной группе в категориях пациентов с размером новообразования до 0,5 см и с размерами от 0,5 до 1,0 см, то разница составит 15,7 %, т. е. в группе исследования новообразования регистрировались значимо чаще, чем в контрольной группе (р˂0,001). При размерах новообразования более 1,0 см в диаметре, существенных различий между группами контроля и исследования не обнаружено. Биопсия выполнялась на 13 % чаще в группе исследования по сравнению с контрольной группой. Заключение. Система искусственного интеллекта наглядно продемонстрировала свою эффективность в детекции новообразований любых размеров; чувствительность составила 80,7 %. Вероятность обнаружения новообразований менее 1,0 см в диаметре при использовании была выше на 13,7 %, вероятность обнаружения тубулярных аденом всех размеров выше на 9,7 %.
- Open Access
- 7 December 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (6) , 19-25
Effectiveness of a modified biopsy technique in endobronchial ultrasound (EBUS) in the diagnosis of peripheral lung neoplasms: results of a clinical study
Introduction. The problem of lung malignant neoplasms diagnosis is extremely urgent. Verification of peripheral lung malignancies using ultrasound bronchoscopy does not exceed 70.6 %.The aim of the work is to demonstrate an increase in the verification of peripheral lung malignancies by endobronchial lung ultrasound examination.Materials and methods The study was conducted on the basis of the endoscopic department of the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine from 2019 to 2021, in which 142 patients were included. The patients were divided into 2 groups. The main group included 68 patients whose examination included fibrobronchoscopy with endo ultrasound with biopsy according to a modified technique. The comparison group included 74 patients who underwent ultrasound bronchoscopy with biopsy according to the standard technique. The manipulation time with biopsy according to the standard technique ranged from 12 to 42 minutes, on the average 29 ± 5 minutes. Ultrasound bronchoscopy with biopsy to the modified technique lasted from 14 to 44 minutes, on average – 30 ± 5 minutes.Results The modified technique of biopsy with endosonographic control of endoscopic instrument position in the pathological focus during ultrasound bronchoscopy allows to increase the percentage of peripheral lung malignant neoplasms verification by 19.8% (p < 0.05). Ultrasound bronchoscopy with biopsy according to a modified technique is a relatively safe manipulation, complications were detected in 2.9 % of patients and were successfully treated conservatively.Discussion Endobronchial ultrasound examination of the lungs is a sufficiently effective and informative technique. Introduction of modified biopsy technique into clinical practice and its wide application will allow to replace more invasive and traumatic diagnostic procedures, to increase informative value of ultrasound bronchoscopy.Conclusion The use of a modified biopsy technique during ultrasound bronchoscopy will increase the verification by 19.8 % (p < 0.05), thus allowing to reduce the period of examination of patients and prescribe antitumor treatment earlier.
- 7 December 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (6) , 19-25
Open AccessEffectiveness of a modified biopsy technique in endobronchial ultrasound (EBUS) in the diagnosis of peripheral lung neoplasms: results of a clinical study
Introduction. The problem of lung malignant neoplasms diagnosis is extremely urgent. Verification of peripheral lung malignancies using ultrasound bronchoscopy does not exceed 70.6 %.The aim of the work is to demonstrate an increase in the verification of peripheral lung malignancies by endobronchial lung ultrasound examination.Materials and methods The study was conducted on the basis of the endoscopic department of the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine from 2019 to 2021, in which 142 patients were included. The patients were divided into 2 groups. The main group included 68 patients whose examination included fibrobronchoscopy with endo ultrasound with biopsy according to a modified technique. The comparison group included 74 patients who underwent ultrasound bronchoscopy with biopsy according to the standard technique. The manipulation time with biopsy according to the standard technique ranged from 12 to 42 minutes, on the average 29 ± 5 minutes. Ultrasound bronchoscopy with biopsy to the modified technique lasted from 14 to 44 minutes, on average – 30 ± 5 minutes.Results The modified technique of biopsy with endosonographic control of endoscopic instrument position in the pathological focus during ultrasound bronchoscopy allows to increase the percentage of peripheral lung malignant neoplasms verification by 19.8% (p < 0.05). Ultrasound bronchoscopy with biopsy according to a modified technique is a relatively safe manipulation, complications were detected in 2.9 % of patients and were successfully treated conservatively.Discussion Endobronchial ultrasound examination of the lungs is a sufficiently effective and informative technique. Introduction of modified biopsy technique into clinical practice and its wide application will allow to replace more invasive and traumatic diagnostic procedures, to increase informative value of ultrasound bronchoscopy.Conclusion The use of a modified biopsy technique during ultrasound bronchoscopy will increase the verification by 19.8 % (p < 0.05), thus allowing to reduce the period of examination of patients and prescribe antitumor treatment earlier.
- 2 December 2022
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 103 (6) , 937-946
The effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine on self-assessment of depression manifestations in women receiving radiotherapy after surgical treatment of uterine cancer
Background. The detection of cancer and its subsequent treatment contribute to the development of depression. This circumstance illustrates the need for proactive prevention of affective status disorders in cancer patients, its dynamic control and timely correction. Aim. Comparative analysis of the effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine (methylethylpyridinol, ethylmethylhydroxypyridine malate, ethylmethylhydroxypyridine succinate) on the dynamics of self-assessment of depression manifestations in women recieving radiation therapy after surgical treatment of uterine cancer. Material and methods. A short-term, prospective, simple blind, placebo-controlled, randomized study of the effect of methylethylpyridinol, ethylmethylhydroxypyridine malate and ethylmethylhydroxypyridine succinate on the severity of depression symptoms in patients receiving radiation therapy after extended extirpation of the uterus with appendages was performed. The study was completed by 96 patients. Course two-week administration of drugs in almost equimolar single doses (0.830.88 mmol) was started simultaneously with radiation therapy. The treatment effectiveness was assessed using the Beck Depression Inventory 2 and 4 weeks after the start of the study. Statistical comparison of related samples was carried out using the Friedman test and post hoc analysis using the paired Wilcoxon test with the Bonferroni correction. Independent samples were compared using the KruskalWallis test with a post hoc analysis using the DanBonferroni test. Results. Radiation therapy was found to cause a clinically significant increase in the severity of depressive symptoms in 14 and 28 days after the start of the study (p 0.010). Two-week administration of methylethylpyridinol, ethylmethylhydroxypyridine malate, and ethylmethylhydroxypyridine succinate reduced the severity of depressive symptoms to the normal level (p 0.001), mainly due to a decrease in the severity of symptoms of the cognitive-affective cluster (p 0.001). The studied drugs with equal severity prevented the escalation of depression symptoms according to the Beck Depression Inventory (p ˃0.05). Conclusion. Hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine are equally effective in preventing the development of depression during postoperative radiation treatment of patients with ute-rine cancer.
- 2 December 2022
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 103 (6) , 937-946
The effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine on self-assessment of depression manifestations in women receiving radiotherapy after surgical treatment of uterine cancer
Background. The detection of cancer and its subsequent treatment contribute to the development of depression. This circumstance illustrates the need for proactive prevention of affective status disorders in cancer patients, its dynamic control and timely correction. Aim. Comparative analysis of the effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine (methylethylpyridinol, ethylmethylhydroxypyridine malate, ethylmethylhydroxypyridine succinate) on the dynamics of self-assessment of depression manifestations in women recieving radiation therapy after surgical treatment of uterine cancer. Material and methods. A short-term, prospective, simple blind, placebo-controlled, randomized study of the effect of methylethylpyridinol, ethylmethylhydroxypyridine malate and ethylmethylhydroxypyridine succinate on the severity of depression symptoms in patients receiving radiation therapy after extended extirpation of the uterus with appendages was performed. The study was completed by 96 patients. Course two-week administration of drugs in almost equimolar single doses (0.830.88 mmol) was started simultaneously with radiation therapy. The treatment effectiveness was assessed using the Beck Depression Inventory 2 and 4 weeks after the start of the study. Statistical comparison of related samples was carried out using the Friedman test and post hoc analysis using the paired Wilcoxon test with the Bonferroni correction. Independent samples were compared using the KruskalWallis test with a post hoc analysis using the DanBonferroni test. Results. Radiation therapy was found to cause a clinically significant increase in the severity of depressive symptoms in 14 and 28 days after the start of the study (p 0.010). Two-week administration of methylethylpyridinol, ethylmethylhydroxypyridine malate, and ethylmethylhydroxypyridine succinate reduced the severity of depressive symptoms to the normal level (p 0.001), mainly due to a decrease in the severity of symptoms of the cognitive-affective cluster (p 0.001). The studied drugs with equal severity prevented the escalation of depression symptoms according to the Beck Depression Inventory (p ˃0.05). Conclusion. Hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine are equally effective in preventing the development of depression during postoperative radiation treatment of patients with ute-rine cancer.
- Open Access
- 28 October 2022
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 26 (4) , 121-128
Improving the quality of diagnosis and verification of peripheral lung neoplasms by using a modified biopsy technique for ultrasonic bronchoscopy (EBUS)
BACKGROUND: The problem of diagnosis and treatment of malignant neoplasms of the lungs is extremely relevant. Verification of the malignant process in the case of peripheral localization of the neoplasm in the lung when using ultrasound bronchoscopy does not exceed 70.6%. AIMS: This study aimed to improve the effectiveness of ultrasound bronchoscopy in the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine by introducing into clinical practice a modified biopsy technique for ultrasound bronchoscopy. The technique is patented, patent for invention no. RU2719666 C1. MATERIALS AND METHODS: From 2019 to 2021, a study was conducted based on the endoscopic department of the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, which included 137 patients. The patients were divided into two groups: the main group included 66 patients in whose examination FBS with endoussis with biopsy by a modified technique was used; the comparison group included 71 patients who underwent ultrasound bronchoscopy with biopsy by a standard technique. The time of biopsy manipulation according to the standard procedure ranged from 14 to 41 min, averaging 305 min. Ultrasound bronchoscopy with biopsy by a modified technique lasted from 16 to 45 minutes, on average 315 min. RESULTS: In the main group, where FBS with ENDOUSSI with biopsy was used in the diagnosis of patients using a modified technique with endosonographic control of the position of the endoscopic instrument in the pathological focus, the diagnosis of malignant neoplasm was verified in 52 patients (in 78.8% of cases). In the comparison group, where the standard biopsy technique was used in patients with ultrasound bronchoscopy, the diagnosis of malignant neoplasm was verified in 41 patients (in 57.7% of cases). Thus, the verification of peripheral lung malignancies when using a modified biopsy technique increases by 21.1% (p 0.05). FBS with endoussis with biopsy using a modified technique is satisfactorily tolerated by patients and is a relatively safe manipulation. CONCLUSION: modified biopsy technique developed by us with endosonographic control of the position of the endoscopic instrument in the pathological focus during ultrasound bronchoscopy makes it possible to increase the percentage of verification of peripheral lung malignancies by 21.1% (p 0.05). The introduction and widespread use of the modified biopsy technique for ultrasound bronchoscopy in the diagnosis of peripheral lung malignancies will reduce the time of examination of patients and prescribe antitumor treatment earlier.
- 28 October 2022
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 26 (4) , 121-128
Open AccessImproving the quality of diagnosis and verification of peripheral lung neoplasms by using a modified biopsy technique for ultrasonic bronchoscopy (EBUS)
BACKGROUND: The problem of diagnosis and treatment of malignant neoplasms of the lungs is extremely relevant. Verification of the malignant process in the case of peripheral localization of the neoplasm in the lung when using ultrasound bronchoscopy does not exceed 70.6%. AIMS: This study aimed to improve the effectiveness of ultrasound bronchoscopy in the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine by introducing into clinical practice a modified biopsy technique for ultrasound bronchoscopy. The technique is patented, patent for invention no. RU2719666 C1. MATERIALS AND METHODS: From 2019 to 2021, a study was conducted based on the endoscopic department of the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, which included 137 patients. The patients were divided into two groups: the main group included 66 patients in whose examination FBS with endoussis with biopsy by a modified technique was used; the comparison group included 71 patients who underwent ultrasound bronchoscopy with biopsy by a standard technique. The time of biopsy manipulation according to the standard procedure ranged from 14 to 41 min, averaging 305 min. Ultrasound bronchoscopy with biopsy by a modified technique lasted from 16 to 45 minutes, on average 315 min. RESULTS: In the main group, where FBS with ENDOUSSI with biopsy was used in the diagnosis of patients using a modified technique with endosonographic control of the position of the endoscopic instrument in the pathological focus, the diagnosis of malignant neoplasm was verified in 52 patients (in 78.8% of cases). In the comparison group, where the standard biopsy technique was used in patients with ultrasound bronchoscopy, the diagnosis of malignant neoplasm was verified in 41 patients (in 57.7% of cases). Thus, the verification of peripheral lung malignancies when using a modified biopsy technique increases by 21.1% (p 0.05). FBS with endoussis with biopsy using a modified technique is satisfactorily tolerated by patients and is a relatively safe manipulation. CONCLUSION: modified biopsy technique developed by us with endosonographic control of the position of the endoscopic instrument in the pathological focus during ultrasound bronchoscopy makes it possible to increase the percentage of verification of peripheral lung malignancies by 21.1% (p 0.05). The introduction and widespread use of the modified biopsy technique for ultrasound bronchoscopy in the diagnosis of peripheral lung malignancies will reduce the time of examination of patients and prescribe antitumor treatment earlier.
- Open Access
- 15 July 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (2) , 177-183
The effect of antioxidant drugs on the self-assessment of clinical symptoms in women during radiation therapy after surgical treatment of endometrial cancer: Placebo-controlled randomized trial
Aim. Comparative analysis of the effect of methylethylpiridinol (Emoxipine), ethylmethylhydroxypyridine malate (Ethoxidol) and ethylmethylhydroxypyridine succinate (Mexidol) on the self-assessment of nonspecific clinical symptoms in women receiving adjuvant radiation therapy after radical surgical treatment of uterine body cancer. Materials and methods. A short-term, prospective, simple blind, placebo-controlled, randomized study of the effect of 14-day course use of emoxipine (150 mg [0.87 mmol] per day intravenously), ethoxidol (225 mg [0.83 mmol] per day intravenously) and mexidol (225 mg [0.88 mmol] daily intravenously) on the dynamics of self-assessment of nonspecific clinical symptoms in patients during radiotherapy after surgical treatment of endometrial cancer was conducted. Self-assessment of clinical symptoms and quality of life (QOL) was studied using the MDASI questionnaire (M.D. Anderson Symptom Inventory). The emotional complaints were assessed using the Giessen questionnaire. Results. The 14-day use of Emoxipine, Ethoxidol and Mexidol in almost eqimolar single doses prevented the negative impact of radiation therapy on the self-assessment of clinical symptoms and QOL according to MDASI. This was manifested by a significant decrease in weakness, sadness and depression, as well as the prevention of nausea and appetite disorders during radiation therapy. At the same time, the emotional coloring of stomach and heart complaints, exhaustion and pressure of complaints decreased according to the Giessen questionnaire. The positive effect of Emoxipine, Ethoxidol and Mexidol on the self-assessment of the clinical condition and the emotional coloring of the corresponding complaints was accompanied by an improvement in such components of QOL as general activity, mood, ability to work, relationships with other people and ability to enjoy life. The studied drugs did not differ in the intensenty of the identified effects. Conclusion. Emoxipine, Ethoxidol and Mexidol significantly improve the multidimensional self-assessment of the clinical condition of patients receiving radiation therapy after surgical treatment of endometrial cancer. The results obtained allow us to consider Emoxipine, Ethoxidol and Mexidol as equally effective means of maintenance therapy at the stage of postoperative radiation treatment of patients with endometrial cancer.
- 15 July 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (2) , 177-183
Open AccessThe effect of antioxidant drugs on the self-assessment of clinical symptoms in women during radiation therapy after surgical treatment of endometrial cancer: Placebo-controlled randomized trial
Aim. Comparative analysis of the effect of methylethylpiridinol (Emoxipine), ethylmethylhydroxypyridine malate (Ethoxidol) and ethylmethylhydroxypyridine succinate (Mexidol) on the self-assessment of nonspecific clinical symptoms in women receiving adjuvant radiation therapy after radical surgical treatment of uterine body cancer. Materials and methods. A short-term, prospective, simple blind, placebo-controlled, randomized study of the effect of 14-day course use of emoxipine (150 mg [0.87 mmol] per day intravenously), ethoxidol (225 mg [0.83 mmol] per day intravenously) and mexidol (225 mg [0.88 mmol] daily intravenously) on the dynamics of self-assessment of nonspecific clinical symptoms in patients during radiotherapy after surgical treatment of endometrial cancer was conducted. Self-assessment of clinical symptoms and quality of life (QOL) was studied using the MDASI questionnaire (M.D. Anderson Symptom Inventory). The emotional complaints were assessed using the Giessen questionnaire. Results. The 14-day use of Emoxipine, Ethoxidol and Mexidol in almost eqimolar single doses prevented the negative impact of radiation therapy on the self-assessment of clinical symptoms and QOL according to MDASI. This was manifested by a significant decrease in weakness, sadness and depression, as well as the prevention of nausea and appetite disorders during radiation therapy. At the same time, the emotional coloring of stomach and heart complaints, exhaustion and pressure of complaints decreased according to the Giessen questionnaire. The positive effect of Emoxipine, Ethoxidol and Mexidol on the self-assessment of the clinical condition and the emotional coloring of the corresponding complaints was accompanied by an improvement in such components of QOL as general activity, mood, ability to work, relationships with other people and ability to enjoy life. The studied drugs did not differ in the intensenty of the identified effects. Conclusion. Emoxipine, Ethoxidol and Mexidol significantly improve the multidimensional self-assessment of the clinical condition of patients receiving radiation therapy after surgical treatment of endometrial cancer. The results obtained allow us to consider Emoxipine, Ethoxidol and Mexidol as equally effective means of maintenance therapy at the stage of postoperative radiation treatment of patients with endometrial cancer.
- 1 April 2022
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 85 (3) , 25-32
Влияние эмоксипина, этоксидола и мексидола на качество жизни женщин, получающих лучевую терапию после хирургического лечения рака тела матки
Проведено краткосрочное, проспективное, простое «слепое», плацебо-контролируемое, рандомизированное исследование влияния эмоксипина, этоксидола и мексидола на динамику «связанного со здоровьем качества жизни» (health-related quality of life (HRQoL)) у пациенток, получающих лучевую терапию после хирургического лечения рака тела матки. Установлено, что адьювантная лучевая терапия после хирургического лечения рака тела матки вызывает снижение HRQoL по данным генерического (SF-36) и онкоспецифического (FACT-En) инструментов самооценки HRQoL. Наиболее выраженное снижение (на 20 – 30 % от исходного уровня; p < 0,001) отмечается для таких компонентов HRQoL, как «VT — жизненная активность» (по SF-36) и «PWB — физическое благополучие» (по FACT-En). Внутривенное капельное введение эмоксипина, этоксидола и мексидола в практически эквимолярных разовых дозах (0,83 – 0,88 ммоль) в течение 14 дней на фоне лучевой терапии предотвращает её негативное влияние на HRQoL (по SF-36), вызывая прирост «VT — жизненной активности», «SF — социального функционирования», «МН — психического здоровья», «PH — физического компонента здоровья» и «МН — психологического компонента здоровья» на 4 – 93 % по сравнению с «активной плацебо-терапией» (p < 0,001). Наиболее выраженный прирост (в 3 – 4 раза; p < 0,001) отмечается для «RP — ролевого физического функционирования» и «RE — ролевого эмоционального функционирования». Одновременно все изученные препараты улучшали онкоспецифичные параметры HRQoL (по FACT-En). Это проявилось нарастанием «PWB — физического благополучия», «EWB — эмоционального благополучия», показателя добавочной шкалы для больных раком эндометрия («EnCS») и интегрального показателя FACT-En («TS») на 13 – 38 % по сравнению с «активной плацебо-терапией» (p < 0,001). Наиболее выраженной HRQoL-протекторной активностью обладал этоксидол, оказавшийся единственным из изученных препаратов способным повышать онкоспецифичный показатель «FWB — функциональное благополучие» (на 13 % в сравнении с «активной-плацебо-терапией»; p = 0,01).
- 1 April 2022
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 85 (3) , 25-32
Влияние эмоксипина, этоксидола и мексидола на качество жизни женщин, получающих лучевую терапию после хирургического лечения рака тела матки
Проведено краткосрочное, проспективное, простое «слепое», плацебо-контролируемое, рандомизированное исследование влияния эмоксипина, этоксидола и мексидола на динамику «связанного со здоровьем качества жизни» (health-related quality of life (HRQoL)) у пациенток, получающих лучевую терапию после хирургического лечения рака тела матки. Установлено, что адьювантная лучевая терапия после хирургического лечения рака тела матки вызывает снижение HRQoL по данным генерического (SF-36) и онкоспецифического (FACT-En) инструментов самооценки HRQoL. Наиболее выраженное снижение (на 20 – 30 % от исходного уровня; p < 0,001) отмечается для таких компонентов HRQoL, как «VT — жизненная активность» (по SF-36) и «PWB — физическое благополучие» (по FACT-En). Внутривенное капельное введение эмоксипина, этоксидола и мексидола в практически эквимолярных разовых дозах (0,83 – 0,88 ммоль) в течение 14 дней на фоне лучевой терапии предотвращает её негативное влияние на HRQoL (по SF-36), вызывая прирост «VT — жизненной активности», «SF — социального функционирования», «МН — психического здоровья», «PH — физического компонента здоровья» и «МН — психологического компонента здоровья» на 4 – 93 % по сравнению с «активной плацебо-терапией» (p < 0,001). Наиболее выраженный прирост (в 3 – 4 раза; p < 0,001) отмечается для «RP — ролевого физического функционирования» и «RE — ролевого эмоционального функционирования». Одновременно все изученные препараты улучшали онкоспецифичные параметры HRQoL (по FACT-En). Это проявилось нарастанием «PWB — физического благополучия», «EWB — эмоционального благополучия», показателя добавочной шкалы для больных раком эндометрия («EnCS») и интегрального показателя FACT-En («TS») на 13 – 38 % по сравнению с «активной плацебо-терапией» (p < 0,001). Наиболее выраженной HRQoL-протекторной активностью обладал этоксидол, оказавшийся единственным из изученных препаратов способным повышать онкоспецифичный показатель «FWB — функциональное благополучие» (на 13 % в сравнении с «активной-плацебо-терапией»; p = 0,01).